D. Boral Capital Reiterates “Buy” Rating for Artelo Biosciences (NASDAQ:ARTL)

D. Boral Capital restated their buy rating on shares of Artelo Biosciences (NASDAQ:ARTL) in a research note issued to investors on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $6.00 price objective on the stock.

A number of other equities analysts also recently issued reports on ARTL. LADENBURG THALM/SH SH raised Artelo Biosciences to a “strong-buy” rating in a report on Wednesday, December 25th. EF Hutton Acquisition Co. I raised Artelo Biosciences to a “strong-buy” rating in a research report on Tuesday, October 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Artelo Biosciences in a research report on Monday, December 9th.

Artelo Biosciences Price Performance

Artelo Biosciences stock opened at $1.14 on Tuesday. The business’s fifty day moving average is $1.09 and its 200 day moving average is $1.19. The stock has a market capitalization of $3.68 million, a PE ratio of -0.40 and a beta of 1.25. Artelo Biosciences has a one year low of $0.91 and a one year high of $1.75.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.06. As a group, sell-side analysts expect that Artelo Biosciences will post -2.62 EPS for the current fiscal year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.